Cystic fibrosis transmembrane conductance regulator modulators attenuate platelet activation and aggregation in blood of healthy donors and COVID-19 patients. Issue 3 (23rd March 2023)
- Record Type:
- Journal Article
- Title:
- Cystic fibrosis transmembrane conductance regulator modulators attenuate platelet activation and aggregation in blood of healthy donors and COVID-19 patients. Issue 3 (23rd March 2023)
- Main Title:
- Cystic fibrosis transmembrane conductance regulator modulators attenuate platelet activation and aggregation in blood of healthy donors and COVID-19 patients
- Authors:
- Asmus, Erik
Karle, Weronika
Brack, Markus C.
Wittig, Corey
Behrens, Felix
Reinshagen, Leander
Pfeiffer, Moritz
Schulz, Sabrina
Mandzimba-Maloko, Bertina
Erfinanda, Lasti
Perret, Paul L.
Michalick, Laura
Smeele, Patrick J.
Lim, Endry H.T.
van den Brom, Charissa E.
Vonk, Alexander B.A.
Kaiser, Toralf
Suttorp, Norbert
Hippenstiel, Stefan
Sander, Leif E.
Kurth, Florian
Rauch, Ursula
Landmesser, Ulf
Haghikia, Arash
Preissner, Robert
Bogaard, Harm J.
Witzenrath, Martin
Kuebler, Wolfgang M.
Szulcek, Robert
Simmons, Szandor - Abstract:
- Cystic fibrosis transmembrane conductance regulator (CFTR) modulators reduce agonist-induced platelet activation and function. CFTR modulators, such as ivacaftor, present a promising therapeutic strategy in thrombocytopathies, including severe COVID-19. https://bit.ly/3HJykdt Recent work identified the chloride channel cystic fibrosis transmembrane conductance regulator (CFTR), mutations of which can cause cystic fibrosis (CF), as an important regulator of platelet function, in that its loss or inhibition causes agonist-induced platelet hyperactivation [1]. Hence, activation of CFTR may conversely present a novel strategy to counteract platelet hypercoagulability. Of late, several groups of CFTR modulators have been clinically approved to boost the abundance and/or channel open probability of CFTR at the cell membrane in CF patients. While originally targeted for specific CFTR mutations, emerging evidence suggests that CFTR modulators may also increase channel activity of wild-type CFTR (CFTRwt ).
- Is Part Of:
- European respiratory journal. Volume 61:Issue 3(2023)
- Journal:
- European respiratory journal
- Issue:
- Volume 61:Issue 3(2023)
- Issue Display:
- Volume 61, Issue 3 (2023)
- Year:
- 2023
- Volume:
- 61
- Issue:
- 3
- Issue Sort Value:
- 2023-0061-0003-0000
- Page Start:
- Page End:
- Publication Date:
- 2023-03-23
- Subjects:
- Respiratory organs -- Diseases -- Periodicals
Respiration -- Periodicals
616.2 - Journal URLs:
- http://erj.ersjournals.com ↗
http://www.ersnet.org ↗
http://www.blackwell-synergy.com/member/institutions/issuelist.asp?journal=mrj ↗
http://www.ingenta.com/journals/browse/ers/erj?mode=direct ↗ - DOI:
- 10.1183/13993003.02009-2022 ↗
- Languages:
- English
- ISSNs:
- 0903-1936
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 26740.xml